Skip to main content
OpenTrials
Completed

NCT Number: NCT00472940

Prevalence of Hypogonadism in Male Cancer Patients

Cancer and its complications are common problems. In most cases, this condition has a profound impact on survival and quality of life (QoL). Fatigue, sexual dysfunction, decreased sexual drive, depression and poor appetite are commonly seen in these patients. However, these symptoms also are seen in men with other conditions including those with low testosterone levels.

The objective of this study is to determine the number of male patients with cancer that have low testosterone levels and to establish the relationship between testosterone levels and the symptoms that these patients experience.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Body Weight Body Weight Changes Cachexia Endocrine System Diseases Gonadal Disorders Hypogonadism Neoplasms Pathological Conditions, Signs and Symptoms Signs and Symptoms Thinness Weight Loss

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Michael E. DeBakey Veterans Affairs Medical Center

Houston, Texas, 77030, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male subjects ≥ 18 years of age with histological diagnosis of cancer for cancer group.
  • Provide written informed consent prior to screening.
  • Histological diagnosis of cancer other than non-melanoma skin cancer for the two cancer groups.

Exclusion criteria

  • Concomitant use of GH, Megestrol, Marinol, or any other anabolic agent, appetite stimulant (including corticosteroids other than dexamethasone at the time of IV chemotherapy administrations), tube feedings, or parenteral nutrition during the 3 months prior to entering the study.
  • Participation in a clinical trial with investigational agents within 1 month of enrollment.
  • Prior or current use of other medications that interfere with gonadal axis (androgens, estrogens, anti-androgens, etc).

Sponsors and collaborators

Lead sponsor

Baylor College of Medicine

Other

Collaborators

  • Michael E. DeBakey VA Medical Center
  • Solvay Pharmaceuticals

Registry information

Important dates

Study start
2006
Primary completion
2020
Study completion
2020
First posted
May 14, 2007
Registry last updated
Nov 27, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.